secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition Corp. (DMAA)
CIK:        0002028614
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001213900-25-016602
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Drugs Made In America Acquisition Corp. announces separate trading of shares and rights starting Feb 25
--------------------------------------------------------------------------------

- Effective Feb 25, 2025, holders of units (DMAAU) may separate into ordinary shares (DMAA) and rights (DMAAR).
- Units not separated continue to trade on Nasdaq under DMAAU; separated shares and rights trade under DMAA and DMAAR.
- Holders must contact VStock Transfer LLC via their broker to effect the separation; no fractional rights issued.
- The company's IPO units were offered under registration statement effective Jan 7, 2025, with post-effective amendment Jan 27, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2028614/000121390025016602/0001213900-25-016602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2028614/000121390025016602/ea0231980-8k_drugs.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-016602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer